Wang Xiao-Lin, Wang Qing-Qing, Song Hai-Feng
Guangxi Medical University, Nanning 530002, China.
Yao Xue Xue Bao. 2012 Jul;47(7):850-5.
RNA interference (RNAi), as a new technology of gene therapy, has been used in the studies of many diseases in vitro, however, targeting delivery of small interference RNA (siRNA) is still a bottleneck for clinical therapy of siRNA agents. Aptamer is a group of oligonucleotides with high affinity and targeting, and is becoming another important means of delivery for siRNA. In this review, we summarized siRNA delivery obstacles in vivo and recent attractive developments increatively using cell-internalizing aptamers to deliver siRNAs to target cells.
RNA干扰(RNAi)作为一种新的基因治疗技术,已在许多疾病的体外研究中得到应用,然而,小干扰RNA(siRNA)的靶向递送仍是siRNA药物临床治疗的一个瓶颈。适体是一类具有高亲和力和靶向性的寡核苷酸,正成为siRNA递送的另一种重要手段。在这篇综述中,我们总结了体内siRNA递送的障碍以及最近利用细胞内化适体将siRNA递送至靶细胞的有吸引力的创新性进展。